Cryptococcus

Clinical Mycology

Volumn , Issue , 2009, Pages 231-249

  Viviani, Marianna A ^a   Maria Tortorano, Anna ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 76749108736     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4160-5680-5.00009-8     Document Type: Chapter

References (244)

1. Busse O. Über parasitäre Zelleinschlüsse und ihre Züchtung. Zbl Bakt I Abt 1894, 16:175.
2. Sanfelice F. Contributo alla morfologia e biologia dei blastomiceti che si sviluppano nei succhi di alcuni frutti. Ann Ig R Univ Roma 1894, 4:463.
3. Sanfelice F. Sull'azione patogena dei blastomiceti. Ann Ig R Univ Roma 1895, 5:239.
4. Vuillemin P. Les blastomycètes pathogens. Rev Gen Sci 1901, 12:732.
5. Kwon-Chung K.J. A new genus, Filobasidiella, the perfect state of Cryptococcus neoformans. Mycologia 1975, 67:1197.
6. Kwon-Chung K.J. A new species of Filobasidiella, the sexual state of Cryptococcus neoformans B and C serotypes. Mycologia 1976, 68:942.
7. Boekhout T., Theelen B., Diaz M., et al. Hybrid genotypes in the pathogenic yeast Cryptococcus neoformans. Microbiology 2001, 147:891.
8. Kwon-Chung K.J., Boekhout T., Fell J.W., Diaz M. Proposal to conserve the name Cryptococcus gattii against C. hondurianus and C. bacillisporus (Basidiomycetes, Hymenomycetes, Tremelllomycetidae). Taxon 2002, 51:804.
9. Franzot S.P., Salkin I.F., Casadevall A. Cryptococcus neoformansvar. grubii: separate varietal status for Cryptococcus neoformans serotype A isolates. J Clin Microbiol 1999, 37:838.
10. Loftus B.J., Fung E., Roncaglia P., et al. The genome of the basidiomycetous yeast and human pathogen Cryptococcus neoformans. Science 2005, 307:1321.
11. Drouhet E. Milestones in the history of Cryptococcus and cryptococcosis. J Mycol Méd 1997, 7:10.
12. Littman M.L., Zimmerman L.E. Cryptococcosis 1956, Grune and Stratton, New York.
13. Casadevall A., Perfect J.R. Cryptococcus neoformans 1998, ASM Press, Washington DC.
14. Barnett J.A., Payne R.W., Yarrow D. Yeasts: characteristics and identification 1990, Cambridge University Press, Cambridge, p. 282. 2nd edn.
15. Krajden S., Summerbell R.C., Kane J., et al. Normally saprobic cryptococci isolated from Cryptococcus neoformans infections. J Clin Microbiol 1883, 29:1991.
16. Dromer F., Moulignier A., Dupont B., et al. Myeloradiculitis due to Cryptococcus curvatus in AIDS. AIDS 1995, 9:395. (letter).
17. Kordossis T., Avlami A., Velegraki A., et al. First report of Cryptococcus laurentii meningitis and a fatal case of Cryptococcus albidus cryptococcaemia in AIDS patients. Med Mycol 1998, 36:335.
18. Rimek D., Haase G., Luck A., et al. First report of a case of meningitis caused by Cryptococcus adeliensis in a patient with acute myeloid leukemia. J Clin Microbiol 2004, 42:481.
19. Al-Doory Y. The ultrastructure of Cryptococcus neoformans. Sabouraudia 1971, 9:115.
20. Cherniak R., Sundstrom J.B. Polysaccharide antigens of the capsule of Cryptococcus neoformans. Infect Immun 1994, 62:1507.
21. Evans EE.D.E. The antigenic composition of Cryptococcus neoformans. I. A serologic classification by means of the capsular agglutinations. J Immunol 1950, 64:423.
22. Wilson D.E., Bennett J.E., Bailey J.W. Serologic grouping of Cryptococcus neoformans. Proc Soc Exp Biol Med 1968, 127:820.
23. Ikeda R., Shinoda T., Fukazawa Y., Kaufman L. Antigenic characterization of Cryptococcus neoformans serotypes and its application to serotyping of clinical isolates. J Clin Microbiol 1982, 16:22.
24. Dromer F., Guého E., Ronin O., Dupont B. Serotyping of Cryptococcus neoformans by using a monoclonal antibody specific for capsular polysaccharide. J Clin Microbiol 1993, 31:359.
25. Abruzzo G.K., Flattery A.M., Gill C.J., et al. Evaluation of water-soluble pneumocandin analogs L-733560, L-705589, and L-731373 with mouse models of disseminated aspergillosis, candidiasis, and cryptococcosis. Antimicrob Agents Chemother 1995, 39:1077.
26. Ostrosky-Zeichner L., Alexander B.D., Kett D.H., et al. Multicenter clinical evaluation of the (1,3) beta-D-glucan assay as an aid to diagnosis of fungal infections in humans. Clin Infect Dis 2005, 41:654.
27. Lin X., Hull C.M., Heitman J. Sexual reproduction between partners of the same mating type in Cryptococcus neoformans. Nature 2005, 434:1017.
28. Bennett J.E., Kwon-Chung K.J., Theodore T.S. Biochemical differences between serotypes of Cryptococcus neoformans. Sabouraudia 1978, 16:167.
29. Dufait R., Velho R., De Vroey C. Rapid identification of the two varieties of Cryptococcus neoformans by D-proline assimilation. Mykosen 1987, 30:483.
30. Mukamurangwa P., Raes-Wuytack C., De Vroey C. Cryptococcus neoformans var. gattii can be separated from var. neoformans by its ability to assimilate D-tryptophan. J Med Vet Mycol 1995, 33:419.
31. Polacheck I., Kwon-Chung K.J. Creatinine metabolism in Cryptococcus neoformans and Cryptococcus bacillisporus. J Bacteriol 1980, 142:15.
32. Kwon-Chung K.J., Wickes B., Booth J.L., et al. Urease inhibition by EDTA in the two varieties of Cryptococcus neoformans. Infect Immun 1987, 55:1751.
33. Kwon-Chung K.J., Polacheck I., Bennett J.E. Improved diagnostic medium for separation of Cryptococcus neoformans var. neoformans (serotypes A and D) and Cryptococcus neoformans var. gattii (serotypes B and C). J Clin Microbiol 1982, 15:535.
34. Shadomy H.J., Wood-Helie S., Shadomy S., et al. Biochemical serogrouping of clinical isolates of Cryptococcus neoformans. Diagn Microbiol Infect Dis 1987, 6:131.
35. Emmons C.W. Saprophytic sources of Cryptococcus neoformans associated with the pigeon (Columba livia). Am J Hyg 1955, 62:227.
36. Kidd S.E., Bach P.J., Hingston A.O., et al. Cryptococcus gattii dispersal mechanisms, British Columbia, Canada. Emerg Infect Dis 2007, 13:51.
37. MacDougall L., Kidd S.E., Galanis E., et al. Spread of Cryptococcus gattii in British Columbia, Canada, and detection in the Pacific Northwest. USA. Emerg Infect Dis 2007, 13:42.
38. Vogelkot Staib F. Ein Nährsubstrat für die Gattung Cryptococcus. Zbl Bakt I Orig 1962, 186:233.
39. Staib F. New concepts in the occurrence and identification of Cryptococcus neoformans. Mycopathol Mycol Appl 1963, 19:143.
40. Littman M.L., Borok R. Relation of the pigeon to cryptococcosis: natural carrier state, heat resistance and survival of Cryptococcus neoformans. Mycopathol Mycol Appl 1968, 35:329.
41. Eggert C., Temp U., Eriksson K.E. The ligninolytic system of the white rot fungus Pycnoporus cinnabarinus: purification and characterization of the laccase. Appl Environ Microbiol 1996, 62:1151.
42. Lazéra M.S., Pires F.D.A., Camillo-Coura L., et al. Natural habitat of Cryptococcus neoformans var. neoformans in decaying wood forming hollows in living trees. J Med Vet Mycol 1996, 34:127.
43. Ellis D.H., Pfeiffer T.J. Natural habitat of Cryptococcus neoformans var. gattii. J Clin Microbiol 1990, 28:1642.
44. Passoni L.F.C. Wood, animals and human beings as reservoirs for human Cryptococcus neoformans infection. Rev Iberoam Micol 1999, 16:77.
45. Stephen C., Lester S., Black W., et al. Multispecies outbreak cryptococcosis on Southern Vancouver Island, British Columbia. Can J Vet Res 2002, 43:792.
46. Baró T., Torres-Rodríguez J.M., Mendoza M.H., et al. First identification of autochthonous Cryptococcus neoformans var. gattii isolated from goats with predominantly severe pulmonary disease in Spain. J Clin Microbiol 1998, 36:458.
47. Callejas A., Ordoñez N., Rodríguez M.C., Castañeda E. First isolation of Cryptococcus neoformans var. gattii, serotype C, from the environment in Colombia. Med Mycol 1998, 36:341.
48. Montenegro H, Mazzuia E. Isolation of Cryptococcus neoformans var. neoformans in decaying wood forming hollow in a tree of Caesalpinia peltophoroides (Leguminosae), São Paulo, Brazil, Abstract PC27. 4th International Conference on Cryptococcus and Cryptococcosis, London, 1999.
49. Trilles L., Lazera M., Wanke B., et al. Genetic characterization of environmental isolates of the Cryptococcus neoformans species complex from Brazil. Med Mycol 2003, 41:383.
50. Granados D.P., Castaneda E. Isolation and characterization of Cryptococcus neoformans varieties recovered from natural sources in Bogota, Colombia, and study of ecological conditions in the area. Microb Ecol 2005, 49:282.
51. Lazéra M.S., Wanke B., Nishikawa M.M. Isolation of both varieties of Cryptococcus neoformans from saprophytic sources in the city of Rio de Janeiro, Brazil. J Med Vet Mycol 1993, 31:449.
52. Staib F. Cryptococcus neoformans und Guizotia abyssinica (syn. G. oleifera D.C.) Farbreaktion für Cr. neoformans. Zbl Hyg 1962, 148:466.
53. Shields A.B., Ajello L. Medium for selective isolation of Cryptococcus neoformans. Science 1966, 151:208.
54. Staib F., Seeliger H.P.R. Un nouveau milieu sélectif pour l'isolement de C. neoformans des matières fécales et du sol. Ann Inst Pasteur 1966, 110:792.
55. Molecular principles of fungal pathogenesis 2006, ASM Press, Washington DC. J. Heitman, S.G. Filler, J.E. Edwards, A.P. Mitchell (Eds.).
56. Casadevall A. Cards of virulence and the global virulome for humans. Microbe 2006, 1:359.
57. Martinez L.R., Garcia-Rivera J., Casadevall A. Cryptococcus neoformans var. neoformans (serotype D) strains are more susceptible to heat than C. neoformans var. grubii (serotype A) strains. J Clin Microbiol 2001, 39:3365.
58. Odom A., Muir S., Lim E., et al. Calcineurin is required for virulence of Cryptococcus neoformans. EMBO J 1997, 16:2576.
59. Perfect J.R. Cryptococcus neoformans: a sugar-coated killer. Molecular Principles of Fungal Pathogenesis 2006, 281. ASM Press, Washington DC. J. Heitman, S.G. Filler, J.E. Eduards, A.P. Mitchell (Eds.).
60. Drouhet E., Segretain G. Inhibition de la migration leucocytaire in vitro par un polyoside capsulaire de Torulopsis (Cryptococcus) neoformans. Ann Inst Pasteur 1951, 81:674.
61. McGaw T.G., Kozel T.R. Opsonization of Cryptococcus neoformans by human immunoglobulin G: masking of immunoglobulin G by cryptococcal polysaccharide. Infect Immun 1979, 25:262.
62. Kozel T.R., Gotschlich E.C. The capsule of Cryptococcus neoformans passively inhibits phagocytosis of the yeast by macrophages. J Immunol 1982, 129:1675.
63. Vartivarian S.E., Anaissie E.J., Cowart R.E., et al. Regulation of cryptococcal capsular polysaccharide by iron. J Infect Dis 1993, 167:186.
64. Zaragoza O., Fries B.C., Casadevall A. Induction of capsule growth in Cryptococcus neoformans by mammalian serum and CO2. Infect Immun 2003, 71:6155.
65. Murphy J.W., Mosley R.L., Cherniak R., et al. Serological, electrophoretic, and biological properties of Cryptococcus neoformans antigens. Infect Immun 1988, 56:424.
66. Murphy J.W. Slick ways Cryptococcus neoformans foils host defenses. ASM News 1996, 62:77.
67. Nosanchuk J.D., Casadevall A. Cellular charge of Cryptococcus neoformans: contributions from the capsular polysaccharide, melanin, and monoclonal antibody binding. Infect Immun 1997, 65:1836.
68. Feldmesser M., Tucker S., Casadevall A. Intracellular parasitism of macrophages by Cryptococcus neoformans. Trends Microbiol 2001, 9:273.
69. Chang Y.C., Kwon-Chung K.J. Complementation of a capsule-deficient mutation of Cryptococcus neoformans restores its virulence. Mol Cell Biol 1994, 14:4912.
70. Chang Y.C., Penoyer L.A., Kwon-Chung K.J. The second capsule gene of Cryptococcus neoformans, CAP64, is essential for virulence. Infect Immun 1996, 64:1977.
71. Chang Y.C., Kwon-Chung K.J. Isolation of the third capsule-associated gene, CAP60, required for virulence in Cryptococcus neoformans. Infect Immun 1998, 66:2230.
72. Chang Y.C., Kwon-Chung K.J. Isolation, characterization and localization of a capsule-associated gene, CAP10, of Cryptococcus neoformans. J Bacteriol 1999, 181:5636.
73. Moyrand F., Klaproth B., Himmelreich U., et al. Isolation and characterization of capsule structure mutant strains of Cryptococcus neoformans. Mol Microbiol 2002, 45:837.
74. Hopfer R.L., Gröschel D. Six-hour pigmentation test for the identification of Cryptococcus neoformans. J Clin Microbiol 1975, 2:96.
75. Williamson P. Laccase and melanin in the pathogenesis of Cryptococcus neoformans. Front Biosci 1997, 2:99.
76. Zhu X., Williamson P.R. Role of laccase in the biology and virulence of Cryptococcus neoformans. FEMS Yeast Res 2004, 5:1.
77. Doering T.L., Nosanchuk J.D., Roberts W.K., Casadevall A. Melanin as a potential cryptococcal defence against microbicidal proteins. Med Mycol 1999, 37:175.
78. Noverr M.C., Williamson P.R., Fajardo R.S., Huffnagle G.B. CNLAC1 is required for extrapulmonary dissemination of Cryptococcus neoformans but not pulmonary persistence. Infect Immun 2004, 72:1693.
79. Polacheck I., Hearing V.J., Kwon-Chung K.J. Biochemical studies of phenoloxidase and utilization of catecholamines in Cryptococcus neoformans. J Bacteriol 1982, 150:1212.
80. Jacobson E.S., Emery H.S. Temperature regulation of the cryptococcal phenoloxidase. J Med Vet Mycol 1991, 29:121.
81. Kwon-Chung K.J., Edman J.C., Wickes B.L. Genetic association of mating types and virulence in Cryptococcus. Infect Immun 1992, 60:602.
82. Barchiesi F., Cogliati M., Esposto M.C., et al. Comparative analysis of pathogenicity of Cryptococcus neoformans serotypes A, D and AD in murine cryptococcosis. J Infect 2005, 51:10.
83. Nielsen K., Cox G.M., Wang P., et al. Sexual cycle of Cryptococcus neoformans var. grubii and virulence of congenic a and alpha isolates. Infect Immun 2003, 71:4831.
84. Nielsen K., Cox G.M., Litvintseva A.T., et al. Cryptococcus neoformans alpha strains preferentially disseminate to the central nervous system during co-infection. Infect Immun 2005, 73:4922.
85. Fraser J.A., Giles S.S., Wenink E.C., et al. Same-sex mating and the origin of the Vancouver Island Cryptococcus gattii outbreak. Nature 2005, 437:1360.
86. Monari C., Pericolini E., Bistoni G., et al. Influence of indinavir on virulence and growth of Cryptococcus neoformans. J Infect Dis 2005, 191:307.
87. Van Duin D., Casadevall A. Melanization of Cryptococcus neoformans and Histoplasma capsulatum reduces their susceptibilities to amphotericin B and caspofungin. Antimicrob Agents Chemother 2002, 46:3394.
88. Romani L. Immunity to fungal infections. Nat Rev Immunol 2004, 4:1.
89. Shoham S., Levitz S.M. The immune response to fungal infections. Br J Haematol 2005, 129:569.
90. Mansour M.K., Levitz S.M. Interaction of fungi with phagocytes. Curr Opin Microbiol 2002, 5:359.
91. Diamond R.D., Root R.K., Bennett J.E. Factors influencing killing of Cryptococcus neoformans by human leukocytes in vitro. J Infect Dis 1972, 125:367.
92. Miller M.F., Mitchell T.G. Killing of Cryptococcus neoformans strains by human neutrophils and monocytes. Infect Immun 1991, 59:24.
93. Ma L.L., Wang C.L.C., Neely G.G., et al. NK cells use perforin rather than granulysin for anticryptococcal activity. J Immunol 2004, 173:3357.
94. Syme R.M., Spurrel J.C., Amankwah E.K., et al. Primary dendritic cells phagocytose Cryptococcus neoformans via mannose receptors and Fcy receptor II for presentation to T lymphocytes. Infect Immun 2002, 70:5972.
95. Macher A.M., Bennett J.E., Gadek J.E., Frank M.M. Complement depletion in cryptococcal sepsis. J Immunol 1978, 120:1686.
96. Lee S.C., Dickson D.W., Brosnan C.F., Casadevall A. Human astrocytes inhibit Cryptococcus neoformans growth by a nitric oxide-mediated mechanism. J Exp Med 1994, 180:365.
97. Lee S.C., Kress Y., Dickson D.W., Casadevall A. Human microglia mediate anti- Cryptococcus neoformans activity in the presence of specific antibody. J Neuroimmunol 1995, 62:43.
98. Lee S.C., Kress Y., Zhao M.L., et al. Cryptococcus neoformans survive and replicate in human microglia. Lab Invest 1995, 73:871.
99. Yamamoto Y., Kohno S., Koga H., et al. Random amplified polymorphic DNA analysis of clinically and environmentally isolated Cryptococcus neoformans in Nagasaki. J Clin Microbiol 1995, 33:3328.
100. Sorrell T.C., Chen S.C.A., Ruma P., et al. Concordance of clinical and environmental isolates of Cryptococcus neoformans var. gattii by random amplification of polymorphic DNA analysis and PCR fingerprinting. J Clin Microbiol 1996, 34:1253.
101. Beyt B.E., Waltman S.R. Cryptococcal endophthalmitis after corneal transplantation. N Engl J Med 1978, 298:825.
102. Ooi B.S., Chen B.T., Lim C.H., et al. Survival of a patient transplanted with a kidney infected with Cryptococcus neoformans. Transplantation 1971, 11:428.
103. Kanj S.S., Welty-Wolf K., Madden J., et al. Fungal infections in lung and heart-lung transplant recipients. Report of 9 cases and review of the literature. Medicine (Baltimore) 1996, 75:142.
104. Sirinavin S., Intusoma U., Tuntirungsee S. Mother-to-child transmission of Cryptococcus neoformans. Pediatr Infect Dis J 2004, 23:278.
105. Wang C.Y., Wu H.D., Hsueh P.R. Nosocomial transmission of cryptococcosis. N Engl J Med 2005, 352:1271.
106. Powell K.E., Dahl B.A., Weeks R.J., Tosh F.E. Airborne Cryptococcus neoformans: particles from pigeon excreta compatible with alveolar deposition. J Infect Dis 1972, 125:412.
107. Salyer W.R., Salyer D.C., Baker R.D. Primary complex of Cryptococcus and pulmonary lymph nodes. J Infect Dis 1974, 130:74.
108. Cameron M.L., Bartlett J.A., Gallis H.A., Waskin H.A. Manifestations of pulmonary cryptococcosis in patients with acquired immunodeficiency syndrome. Rev Infect Dis 1991, 13:64.
109. Berti E., Monti M., Alessi E., et al. Cryptococcose cutanée primitive. Quelques remarques sur deux nouveaux cas. Bull Soc Fr Mycol Méd 1981, 10:207.
110. Naka W., Masuda M., Konohana A., et al. Primary cutaneous cryptococcosis and Cryptococcus neoformans serotype D. Clin Exper Dermatol 1995, 20:221.
111. Sarosi G.A., Silberfarb P.M., Tosh F.E. Cutaneous cryptococcosis. A sentinel of disseminated disease. Arch Dermatol 1971, 104:1.
112. Hay R.J. Cryptococcus neoformans and cutaneous cryptococcosis. Sem Dermatol 1985, 4:252.
113. Atkinson A.J., Bennett J.E. Experience with a new skin test antigen prepared from Cryptococcus neoformans. Am Rev Respir Dis 1968, 97:637.
114. Kaufman L, Blumer S. Cryptococcosis: the awakening giant. In: The Black and White Yeasts. Washington DC, 1978, p. 176.
115. Graybill J.R., Sobel J., Saag M., et al. Diagnosis and management of increased intracranial pressure in patients with AIDS and cryptococcal meningitis. Clin Infect Dis 2000, 30:47.
116. Hajjeh R.A., Conn L.A., Stephens D.S., et al. Cryptococcosis: population-based multistate active surveillance and risk factors in human immunodeficiency virus-infected persons. J Infect Dis 1999, 179:449.
117. Viviani M.A., Cogliati M., Esposto M.C., et al. Molecular analysis of 311 Cryptococcus neoformans isolates from a 30-month ECMM survey of cryptococcosis in Europe. FEMS Yeast Res 2006, 6:614. and the ECMM Cryptococcosis Study Group.
118. Crowe S.M., Carlin J.B., Stewart K.I., et al. Predictive value of CD4 lymphocyte numbers for the development of opportunistic infections and malignancies in HIV-infected persons. J Acq Immune Defic Syndr 1991, 4:770.
119. Dromer F., Mathoulin S., Dupont B., Laporte A. Epidemiology of cryptococcosis in France: a 9-year survey (1985-1993). Clin Infect Dis 1996, 23:82.
120. Kovacs J.A., Kovacs A.A., Polis M., et al. Cryptococcosis in the acquired immunodeficiency syndrome. Ann Intern Med 1985, 103:533.
121. Swinne D., Deppner M., Maniratunga S., et al. AIDS-associated cryptococcosis in Bujumbura, Burundi: an epidemiological study. J Med Vet Mycol 1991, 29:25.
122. Mirza S.A., Phelan M., Rimland D., et al. The changing epidemiology of cryptococcosis: an update from population based active surveillance into large metropolitan areas, 1992-2000. Clin Infect Dis 2003, 36:789.
123. Speed B., Dunt D. Clinical and host differences between infections with the two varieties of Cryptococcus neoformans. Clin Infect Dis 1995, 21:28.
124. Montagna M.T., Viviani M.A., Pulito A., et al. Cryptococcus neoformans var. gattiiin Italy. Note II. Environmental investigation related to an autochthonous clinical case in Apulia. J Mycol Méd 1997, 7:93.
125. Morgan J., McCarthy K.M., Gould S., et al. Cryptococcus gattii infection: characteristics and epidemiology of cases identified in a South African province with HIV seroprevalence, 2002-2004. Clin Infect Dis 2006, 43:1077.
126. Kwon-Chung K.J., Bennett J.E. Epidemiologic differences between the two varieties of Cryptococcus neoformans. Am J Epidemiol 1984, 120:123.
127. Spitzer E.D., Spitzer S.G., Freundlich L.F., Casadevall A. Persistence of initial infection in recurrent Cryptococcus neoformans meningitis. Lancet 1993, 341:595.
128. Haynes K.A., Sullivan D.J., Coleman D.C., et al. Involvement of multiple Cryptococcus neoformans strains in a single episode of cryptococcosis and reinfection with novel strains in recurrent infection demonstrated by random amplification of polymorphic DNA and DNA fingerprinting. J Clin Microbiol 1995, 33:99.
129. Brandt M.E., Pfaller M.A., Hajjeh R.A., et al. Molecular subtypes and antifungal susceptibilities of serial Cryptococcus neoformans isolates in human immunodeficiency virus-associated cryptococcosis. J Infect Dis 1996, 174:812.
130. Leggiadro R.J., Kline M.W., Hughes W.T. Extrapulmonary cryptococcosis in children with acquired immunodeficiency syndrome. Pediatr Infect Dis J 1991, 10:658.
131. Gendel B.R., Ende M., Norman S.L. Cryptococcosis: review with special reference to apparent association with Hodgkin's disease. Am J Med 1950, 9:343.
132. Husain S., Wagener M.M., Singh N. Cryptococcus neoformans infection in organ transplant recipients: variables influencing clinical characteristics and outcome. Emerg Infect Dis 2001, 7:375.
133. Jenny-Avital E.R., Abadi M. Immune reconstitution cryptococcosis after initiation of successful highly active antiretroviral therapy. Clin Infect Dis 2002, 35:e-128.
134. Singh N., Lortholary O., Alexander B.D., et al. An immune reconstitution syndrome-like illness associated with Cryptococcus neoformans infection in organ transplant recipient. Clin Infect Dis 2005, 40:1756.
135. Campbell G.D. Primary pulmonary cryptococcosis. Am Rev Respir Dis 1966, 94:236.
136. Kerkering T.M., Duma R.J., Shadomy S. The evolution of pulmonary cryptococcosis: clinical implications from a study of 41 patients with and without compromising host factors. Ann Intern Med 1981, 94:611.
137. Lortholary O., Nunez H., Brauner M.W., Dromer F. Pulmonary cryptococcosis. Sem Respir Crit Care Med 2004, 25:145.
138. Khoury M.B., Godwin J.D., Ravin C.E., et al. Thoracic cryptococcosis: immunologic competence and radiologic appearance. Am J Roentgenol 1984, 142:893.
139. Batungwanayo J., Taelman H., Bogaerts J., et al. Pulmonary cryptococcosis associated with HIV-1 infection in Rwanda: a retrospective study of 37 cases. AIDS 1994, 8:1271.
140. Clark R.A., Greer D., Atkinson W., et al. Spectrum of Cryptococcus neoformans infection in 68 patients infected with human immunodeficiency virus. Rev Infect Dis 1990, 12:768.
141. Miller W.T., Edelman J.M., Miller W.T. Cryptococcal pulmonary infection in patients with AIDS: radiographic appearance. Radiology 1990, 175:725.
142. Visnegarwala F., Graviss E.A., Lacke C.E., et al. Acute respiratory failure associated with cryptococcosis in patients with AIDS: analysis of predictive factors. Clin Infect Dis 1998, 27:1231.
143. Gal A.A., Koss M.N., Hawkins J., et al. The pathology of pulmonary cryptococcal infections in the acquired immunodeficiency syndrome. Arch Pathol Lab Med 1986, 110:502.
144. Viviani M.A., Tortorano A.M., Pregliasco F. Monitoring of patients at risk for invasive fungal infections. Rev Iberoam Micol 1996, 13:S72.
145. Mulanovich V.E., Dismukes W.E., Markowitz N. Cryptococcal empyema: case report and review. Clin Infect Dis 1995, 20:1396.
146. Sabetta J.R., Andriole V.T. Cryptococcal infection of the central nervous system. Med Clin North Am 1985, 69:333.
147. Zuger A., Louie E., Holzman R.S., et al. Cryptococcal disease in patients with the acquired immunodeficiency syndrome. Diagnostic features and outcome of treatment. Ann Intern Med 1986, 104:234.
148. Chuck S.L., Sande M.A. Infections with Cryptococcus neoformans in the acquired immunodeficiency syndrome. N Engl J Med 1989, 321:794.
149. Saag M.S., Powderly W.G., Cloud G.A., et al. Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. N Engl J Med 1992, 326:83.
150. Dismukes W.E., Cloud G., Gallis H.A., et al. Treatment of cryptococcal meningitis with combination amphotericin B and flucytosine for four as compared with six weeks. N Engl J Med 1987, 317:334.
151. Patterson T.F., Andriole V.T. Current concepts in cryptococcosis. Eur J Clin Microbiol Infect Dis 1989, 8:457.
152. Tan C.T., Kuan B.B. Cryptococcus meningitis, clinical-CT scan considerations. Neuroradiology 1987, 29:43.
153. Popovich M.J., Arthur R.H., Helmer E. CT of intracranial cryptococcosis. Am J Neuroradiol 1990, 11:139.
154. Himmelreich U., Dzendrowskyj T.E., Allen C., et al. Cryptococcomas distinguished from gliomas with MR spectroscopy: an experimental rat and cell culture study. Radiology 2001, 220:122.
155. Dzendrowskyj T.E., Dolenko B., Sorrell T.C., et al. Diagnosis of cerebral cryptococcoma using a computerized analysis of 1H NMR spectra in an animal model. Diagn Microbiol Infect Dis 2005, 52:101.
156. Park M.K., Hospenthal D.R., Bennett J.E. Treatment of hydrocephalus secondary to cryptococcal meningitis by use of shunting. Clin Infect Dis 1999, 28:629.
157. Kestelyn P., Taelman H., Bogaerts J., et al. Ophthalmic manifestations of infections with Cryptococcus neoformans in patients with the acquired immunodeficiency syndrome. Am J Ophthalmol 1993, 116:721.
158. Johnston S.R.D., Corbett E.L., Foster O., et al. Raised intracranial pressure and visual complications in AIDS patients. J Infect 1992, 24:185.
159. Rex J.H., Larsen R.A., Dismukes W.E., et al. Catastrophic visual loss due to Cryptococcus neoformans meningitis. Medicine (Baltimore) 1993, 72:207.
160. Perry H.D., Donnenfeld E.D. Cryptococcal keratitis after keratoplasty (correspondence). Am J Ophthalmol 1990, 110:320.
161. Alfonso F., Gallo L., Winkler B., Suhrland M.J. Fine needle aspiration cytology of peripheral lymph node cryptococcosis. A report of three cases. Acta Cytol 1994, 38:459.
162. Skiest D.J., Hester L.J., Hardy R.D. Cryptococcal immune reconstitution inflammatory syndrome: report of four cases in three patients and review of the literature. J Infect 2005, 51:e289.
163. Behrman R.E., Masci J.R., Nicholas P. Cryptococcal skeletal infections: case report and review. Rev Infect Dis 1990, 12:181.
164. Cash J.B., Goodman N.L. Cryptococcal infection of the temporal bone. Diagn Microbiol Infect Dis 1983, 1:257.
165. Larsen R.A., Bozzette S., McCutchan J.A., et al. Persistent Cryptococcus neoformans infection of the prostate after successful treatment of meningitis. Ann Intern Med 1989, 111:125.
166. Bloomfield N., Gordon M.A., Elmendorf D.F. Detection of Cryptococcus neoformans antigen in body fluids by latex particle agglutination. Proc Soc Exp Biol Med 1963, 114:64.
167. Dromer F., Salamero J., Contrepois A., et al. Production, characterization, and antibody specificity of a mouse monoclonal antibody reactive with Cryptococcus neoformans capsular polysaccharide. Infect Immun 1987, 55:742.
168. Hamilton J.R., Noble A., Denning D.W., Stevens D.A. Performance of Cryptococcus antigen latex agglutination kits on serum and cerebrospinal fluid specimens of AIDS patients before and after pronase treatment. J Clin Microbiol 1991, 29:333.
169. Haldane D.J.M., Bauman D.S., Chow A.W., et al. False negative latex agglutination test in cryptococcal meningitis. Ann Neurol 1986, 19:412.
170. Tanner D.C., Weinstein M.P., Fedorciw B., et al. Comparison of commercial kits for detection of cryptococcal antigen. J Clin Microbiol 1994, 32:1680.
171. Roux P, Ould-Hocine H, Treney J, Poirot JL. Evaluation of a monoclonal antibody based latex agglutination test for detection of cryptococcal polysaccharide antigen, Abstract 3.20. Third International Conference on Cryptococcus and Cryptococcosis, Paris, 1996.
172. Stockman L., Roberts G.D. Specificity of the latex test for cryptococcal antigen: a rapid, simple method for eliminating interference factors. J Clin Microbiol 1982, 16:965.
173. Shinoda T., Ikeda R., Nishikawa A., et al. Formulation and preliminary testing of a cryptococcal antibody coated latex reagent used with protease pre-treatment. Jpn J Med Mycol 1991, 32(suppl 2):83.
174. Boom W.H., Piper D.J., Ruoff K.L., Ferraro M.J. New cause for false-positive results with the cryptococcal antigen test by latex agglutination. J Clin Microbiol 1985, 22:856.
175. Blevins L.B., Fenn J., Segal H., et al. False-positive cryptococcal antigen latex agglutination caused by disinfectants and soaps. J Clin Microbiol 1995, 33:1674.
176. Campbell C.K., Payne A.L., Teall A.J., et al. Cryptococcal latex antigen test positive in patient with Trichosporon beigelii infection. Lancet 1985, 2:43.
177. Westerink M.A., Amsterdam D., Petell R.J., et al. Septicemia due to DF-2. Cause of a false-positive cryptococcal latex agglutination result. Am J Med 1987, 83:155.
178. Ikeda R., Matsuyama H., Nishikawa A., et al. Comparison of serological and chemical characteristics of capsular polysaccharides of Cryptococcus neoformans var. neoformans serotype A and Cryptococcus albidus var. albidus. Microbiol Immunol 1991, 35:125.
179. Gade W., Hinnefeld S.W., Babcock L.S., et al. Comparison of the Premier cryptococcal antigen enzyme immunoassay and the latex agglutination assay for detection of cryptococcal antigens. J Clin Microbiol 1991, 29:1616.
180. Robinson P.A., Bauer M., Leal M.A.E., et al. Early mycological treatment failure in AIDS-associated cryptococcal meningitis. Clin Infect Dis 1999, 28:82.
181. Dupont B., Denning D.W., Marriott D., et al. Mycoses in AIDS patients. J Med Vet Mycol 1994, 32(suppl 1):65.
182. Feldmesser M., Harris C., Reichberg S., et al. Serum cryptococcal antigen in patients with AIDS. Clin Infect Dis 1996, 23:827.
183. Manfredi R., Moroni A., Mazzoni A., et al. Isolated detection of cryptococcal polysaccharide antigen in cerebrospinal fluid samples from patients with AIDS. Clin Infect Dis 1996, 23:849.
184. Viviani M.A., Tortorano A.M., Grancini A., et al. The diagnosis and management of AIDS patients with mycotic infections. Rapid Methods and Automation in Microbiology and Immunology 1991, p.367. Springer Verlag, New York. A. Vaheri, R.C. Tilton, A. Balows (Eds.).
185. Staib F., Seibold M. Use of the membrane filtration technique and Staib agar for the detection of Cryptococcus neoformans in the urine of AIDS patients - a contribution to diagnosis, therapy and pathogenesis of cryptococcosis. Mycoses 1989, 32:63.
186. Diamond R.D., Bennett J.E. Prognostic factors in cryptococcal meningitis. A study of 111 cases. Ann Intern Med 1974, 80:176.
187. Speed B.R., Kaldor J., Cairns B., Pegorer M. Serum antibody response to active infection with Cryptococcus neoformans and its varieties in immunocompetent subjects. J Med Vet Mycol 1996, 34:187.
188. Chandler F.W., Kaplan W., Ajello L. A Colour Atlas and Textbook of the Histopathology of Mycotic Diseases 1980, Wolfe Medical Publications, London, p. 54.
189. Kwon-Chung K.J., Hill W.B., Bennett J.E. New, special stain for histopathological diagnosis of cryptococcosis. J Clin Microbiol 1981, 13:383.
190. Viviani M.A., Tortorano A.M. Milieu sélectif pour l'isolement de Cryptococcus neoformans des expectorations à flore levuriforme mixte. Bull Soc Fr Mycol Méd 1974, 3:189.
191. Zimmer B.L., Roberts G.D. Rapid selective urease test for presumptive identification of Cryptococcus neoformans. J Clin Microbiol 1979, 10:380.
192. Ruane P.J., Walzer L.J., Gorge W.L. Disseminated infection caused by urease-negative Cryptococcus neoformans. J Clin Microbiol 1988, 26:2224.
193. Bava A.J., Negroni R., Bianchi M. Cryptococcosis produced by a urease negative strain of Cryptococcus neoformans. J Med Vet Mycol 1993, 31:87.
194. Viviani M.A., Wen H., Roverselli A., et al. Identification by polymerase chain reaction fingerprinting of Cryptococcus neoformans serotype AD. J Med Vet Mycol 1997, 35:355.
195. Meyer W., Marszewska K., Amirmostofian M., et al. Molecular typing of global isolates of Cryptococcus neoformans var. neoformans by polymerase chain reaction fingerprinting and randomly amplified polymorphic DNA - a pilot study to standardize techniques on which to base a detailed epidemiological survey. Electrophoresis 1999, 20:1790.
196. Lengeler K.B., Cox G.M., Heitman J. Serotype AD strains of Cryptococcus neoformans are diploid or aneuploid and are heterozygous at the mating-type locus. Infect Immun 2001, 69:115.
197. Meyer W M.C., Castaneda A., Jackson S., et al. Molecular typing of Iberoamerican Cryptococcus neoformans isolates. Emerg Infect Dis 2003, 9:189. and the Iberoamerican Cryptococcal Study Group.
198. Esposto M.C., Cogliati M., Tortorano A.M., Viviani M.A. Determination of Cryptococcus neoformans var. neoformans mating type by multiplex PCR. Clin Microbiol Infect 2004, 10:1092.
199. Powderly W.G., Keath E.J., Sokol-Anderson M., et al. Amphotericin B-resistant Cryptococcus neoformans in a patient with AIDS. Infect Dis Clin Pract 1992, 1:314.
200. Block E.R., Jennings A.E., Bennett J.E. 5-fluorocytosine resistance in Cryptococcus neoformans. Antimicrob Agents Chemother 1973, 3:649.
201. Paugam A., Dupouy-Camet J., Blanche P., et al. Increased fluconazole resistance of Cryptococcus neoformans isolated from a patient with AIDS and recurrent meningitis. Clin Infect Dis 1994, 19:975. [correspondence].
202. Birley H.D.L., Johnson E.M., McDonald P., et al. Azole drug resistance as a cause of clinical relapse in AIDS patients with cryptococcal meningitis. Int J STD AIDS 1995, 6:353.
203. Mondon P., Petter R., Amalfitano G., et al. Heteroresistance to fluconazole and voriconazole in Cryptococcus neoformans. Antimicrob Agents Chemother 1999, 43:1856.
204. Van den Bossche H., Marichal P., Le Jeune L., et al. Effects of itraconazole on cytochrome P-450-dependent sterol 14 alpha-demethylation and reduction of 3-ketosteroids in Cryptococcus neoformans. Antimicrob Agents Chemother 1993, 37:2101.
205. Pfaller M.A., Messer S.A., Boyken L., et al. Global trends in the antifungal susceptibility of Cryptococcus neoformans (1990 to 2004). J Clin Microbiol 2005, 43:2163.
206. Clinical and Laboratory Standards Institute Reference method for broth dilution antifungal susceptibility testing of yeasts. M-27A2 2002, Clinical and Laboratory Standards Institute, Wayne, Pa.
207. Ghannoum M.A., Ibrahim A.S., Fu Y., et al. Susceptibility testing of Cryptococcus neoformans: a microdilution technique. J Clin Microbiol 1992, 30:2881.
208. Ghannoum M.A., Fu Y., Ibrahim A.S., et al. In vitro determination of optimal antifungal combinations against Cryptococcus neoformans and Candida albicans. Antimicrob Agents Chemother 1995, 39:2459.
209. Sanati H., Messer S.A., Pfaller M., et al. Multicenter evaluation of broth microdilution method for susceptibility testing of Cryptococcus neoformans against fluconazole. J Clin Microbiol 1996, 34:1280.
210. Witt M.D., Lewis R.J., Larsen R.A., et al. Identification of patients with acute AIDS-associated cryptococcal meningitis who can be effectively treated with fluconazole: the role of antifungal susceptibility testing. Clin Infect Dis 1996, 22:322.
211. Dannaoui E., Abdul M., Arpin M., et al. Results obtained with various antifungal susceptibility testing methods do not predict early clinical outcome in patients with cryptococcosis. Antimicrob Agents Chemother 2006, 50:2464.
212. Viviani M.A., Esposto M.C., Cogliati M., Tortorano A.M. Flucytosine and cryptococcosis: which in vitro test is the best predictor of outcome?. J Chemother 2003, 15:124.
213. Nguyen M.H., Barchiesi F., McGough D.A., et al. In vitro evaluation of combination of fluconazole and flucytosine against Cryptococcus neoformans var. neoformans. Antimicrob Agents Chemother 1995, 39:1691.
214. Barchiesi F., Gallo D., Caselli F., et al. In-vitro interactions of itraconazole with flucytosine against clinical isolates of Cryptococcus neoformans. J Antimicrob Chemother 1999, 44:65.
215. Bennett J.E., Dismukes W.E., Duma R.J., et al. A comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptococcal meningitis. N Engl J Med 1979, 301:126.
216. Berry A.J., Rinaldi M.G., Graybill J.R. Use of high-dose fluconazole as salvage therapy for cryptococcal meningitis in patients with AIDS. Antimicrob Agents Chemother 1992, 36:690.
217. Larsen R.A., Bozzette S.A., Jones B.E., et al. Fluconazole combined with flucytosine for treatment of cryptococcal meningitis in patients with AIDS. Clin Infect Dis 1994, 19:741.
218. Dromer F., Mathoulin S., Dupont B., et al. Comparison of the efficacy of amphotericin B and fluconazole in the treatment of cryptococcosis in human immunodeficiency virus-negative patients: retrospective analysis of 83 cases. Clin Infect Dis 1996, 22(suppl 2):S154. French Cryptococcosis Study Group.
219. Yamaguchi H., Ikemoto H., Watanabe K., et al. Fluconazole monotherapy for cryptococcosis in non-AIDS patients. Eur J Clin Microbiol Infect Dis 1996, 15:787.
220. Van der Horst C.M., Saag M.S., Cloud G.A., et al. Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. N Engl J Med 1997, 337:15.
221. Pappas P.G., Perfect J.R., Claud G.A., et al. Cryptococcosis in human immunodeficiency virus-negative patients in the era of effective azole therapy. Clin Infect Dis 2001, 33:690.
222. Saag M.S., Graybill R.J., Larsen R.A., et al. Practice guidelines for the management of cryptococcal disease. Clin Infect Dis 2000, 30:710.
223. Perfect J.R., Savani D.V., Durack D.T. Comparison of itraconazole and fluconazole in treatment of cryptococcal meningitis and Candida pyelonephritis in rabbits. Antimicrob Agents Chemother 1986, 29:579.
224. Viviani M.A. Opportunistic fungal infections in patients with acquired immune deficiency syndrome. Chemotherapy (Basel) 1992, 38(suppl 1):35.
225. Bozzette S.A., Larsen R.A., Chiu J., et al. A placebo-controlled trial of maintenance therapy with fluconazole after treatment of cryptococcal meningitis in the acquired immunodeficiency syndrome. N Engl J Med 1991, 324:580.
226. Saag M.S., Cloud G.A., Graybill J.R., et al. A comparison of itraconazole versus fluconazole as maintenance therapy for AIDS-associated cryptococcal meningitis. Clin Infect Dis 1999, 28:291.
227. Kaplan J.E., Masur H., Holmes K.K. Guidelines for preventing opportunistic infections among HIV-infected persons - 2002. MMWR Recomm Rep 2002, 51(RR08):1.
228. Sharkey P.K., Graybill J.R., Johnson E.S., et al. Amphotericin B lipid complex compared with amphotericin B in the treatment of cryptococcal meningitis in patients with AIDS. Clin Infect Dis 1996, 22:315.
229. Leenders A.C., Reiss P., Portegies N.K., et al. Liposomal amphotericin B (AmBisome) compared with amphotericin B both followed by oral fluconazole in the treatment of AIDS-associated cryptococcal meningitis. AIDS 1997, 11:1463.
230. Hamill RJ, Sobel J, El-Sadr W, et al. Randomized double-blind trial of AmBisome (liposomal amphotericin B) and amphotericin B in acute cryptococcal meningitis in AIDS patients, Abstract 1161. 39th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, 1999.
231. Just-Nübling G, Heise W, Rieg G, et al. Triple combination of amphotericin B, flucytosine and fluconazole for treatment of acute cryptococcal meningitis in patients with AIDS, Abstract V.5. 3rd International Conference on Cryptococcus and Cryptococcosis, Paris, 1996.
232. Fujita N.K., Reynard M., Sapico F.L., et al. Cryptococcal intracerebral mass lesions. The role of computed tomography and nonsurgical management. Ann Intern Med 1981, 94:382.
233. Dismukes W.E. Management of cryptococcosis. Clin Infect Dis 1993, 17(suppl 2):S507.
234. Sarosi G.A. Cryptococcal lung disease in patients without HIV infection. Chest 1999, 115:610.
235. Lortholary O., Fontanet A., Memain N., et al. Incidence and risk factors of immune reconstitution inflammatory syndrome complicating HIV-associated cryptococcosis in France. AIDS 2005, 19:1043., et al, French Cryptococcosis Study Group.
236. Reardon C.C., Kim S.J., Wagner R.P., et al. Phagocytosis and growth inhibition of Cryptococcus neoformans by human alveolar macrophages: effects of HIV-1 infection. AIDS 1996, 10:613.
237. Walter J.E., Coffee E.G. Control of Cryptococcus neoformans in pigeon coops by alkalinization. Am J Epidemiol 1968, 87:173.
238. Berg J., Clancy C.J., Nguyen M.H. The hidden danger of primary fluconazole prophylaxis for patients with AIDS. Clin Infect Dis 1998, 26:186.
239. Lecomte I, Meyohas MC, De Sa M, "East Parisian CISIH" group. Relation between decreasing seric CD 4 lymphocytes count and outcome of cryptococcosis in AIDS patients: a basis for new diagnosis strategy, Abstract Th.B.454. VI International Conference on AIDS, San Francisco, 1990.
240. Casadevall A., Pirofki L.A. Feasibility and prospects for a vaccine to prevent cryptococcosis. Med Mycol 2005, 43:667.
241. Kwon-Chung K.J., Bennett J.E., Rhodes J.C. Taxonomic studies on Filobasidiella species and their anamorphs. Antonie van Leeuwenhoek 1982, 48:25.
242. Salkin I.F., Hurd N.J. New medium for differentiation of Cryptococcus neoformans serotype pairs. J Clin Microbiol 1982, 15:169.
243. de Gans J., Schattenkerk J.K.M.E., van Ketel R.J. Itraconazole as maintenance treatment for cryptococcal meningitis in the acquired immune deficiency syndrome. Br Med J 1988, 296:339.
244. de Lalla F., Pellizzer G., Manfrin V., et al. Maintenance therapy for cryptococcosis in patients with AIDS after successful primary therapy: oral fluconazole (300 mg daily) versus oral itraconazole (300 mg daily). Clin Microbiol Infect 1999, 5:567.